Key result
Compared with other oral diabetes drugs, sulphonylurea use was associated with a significantly increased risk of cardiovascular death (RR 1.27; 95% CI 1.18-1.34).
Why the study?
Does sulphonylurea use increase the risk of cardiovascular disease in patients with diabetes compared to other oral diabetes drugs?
Population
33 clinical and observational studies pooling 1,325,446 patients with diabetes
Comparison
Sulphonylureas as a class vs Other oral diabetes drugs (including metformin)
Design
Meta-analysis
Follow-up
range of 0.46-10.4 years
Authors
Loading...
May warrant caution with sulphonylureas when alternatives exist; leaves open whether association reflects confounding or causal harm.
Meta-Analysis (n=1,325,446)
Does sulphonylurea use increase the risk of cardiovascular disease in patients with diabetes compared to other oral diabetes drugs?
Relative Risk: 1.27 (95% CI 1.18–1.34)
In patients with diabetes, sulphonylurea use is associated with an increased risk of cardiovascular mortality and composite cardiovascular events compared to other oral anti-diabetic medications.
Phung et al. (2013) conducted a meta-analysis in Type 2 diabetes (n=1,325,446). Sulphonylurea vs. Other oral diabetes drugs was evaluated on Cardiovascular death (RR 1.27, 95% CI 1.18-1.34). Compared with other oral diabetes drugs, sulphonylurea use was associated with a significantly increased risk of cardiovascular death (RR 1.27; 95% CI 1.18-1.34).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: